Equinox Gold Corp. Common Shares vs Regeneron Pharmaceuticals Inc — how do they compare? Equinox Gold Corp. Common Shares trades at $11.43 (market cap $12.92B), while Regeneron Pharmaceuticals Inc trades at $741.17 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.9× Equinox Gold Corp. Common Shares's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.51%). Which is the better fit depends on your goals — on Pluang, investors hold Equinox Gold Corp. Common Shares for 1 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| EQX | REGN | |
|---|---|---|
Market Cap | $12.92B | $76.14B |
Volume | 9,067,677 | 500,239 |
Sector | Basic Materials | Health |
52-Week High | $18.76 | $852.03 |
52-Week Low | $8.62 | $557.73 |
Typical Hold Time | 1 Days | 107 Days |
Enterprise Value | $13.02B | $70.85B |
Dividend Yield | 0.47% | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.
The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Equinox Gold is a gold mining company with operations in the Americas. It produces gold and develops additional mining projects.
Read more on EQX →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →